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Introduction: Systemic lupus erythematosus (SLE) is characterized by impaired efferocytosis and aberrant activation
of innate immunity. We asked if shedding of MER receptor tyrosine kinase (MerTK) and AXL into soluble (s)
ectodomains was related to immunological and clinical aspects of SLE.
Methods: Levels of sMER and sAXL in the plasma of 107 SLE patients and 45 matched controls were measured by
ELISA. In 40 consecutive SLE patients, we examined potential correlations between either sMER or sAXL and plasma
levels of sCD163, a marker of M2 activation. All three soluble receptors were measured in supernatants of
monocytes/macrophages cultured in various immunological conditions. Membrane expression of MerTK, AXL and
CD163 was assessed by flow cytometry.
Results: Both sMER and sAXL were associated with anti-chromatin and anti-phospholipid autoantibodies, and with
hematological and renal involvement. However, sMER and sAXL did not significantly correlate with each other; sAXL
correlated with growth arrest-specific 6 (Gas6), whereas sMER correlated with reduced free protein S (PROS) levels.
Only sMER showed significant associations with lupus-specific anti-dsDNA, anti-Sm, anti-ribonucleoprotein (anti-RNP)
and anti-Ro60 autoantibodies. Strong correlations with disease activity indices (Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI), complement reduction, titer of circulating anti-dsDNA) were found for sMER, not for sAXL.
Patients with active SLEDAI, nephritis, anti-dsDNA and anti-Ro60 positivity showed higher levels of sMER compared to
controls. Levels of sMER, not sAXL, correlated with sCD163 levels, and these correlated with SLEDAI. Production of sMER
and sCD163 occurred under “M2c” polarizing conditions, whereas sAXL was released upon type-I IFN exposure.
Conclusions: Alterations in homeostasis of anti-inflammatory and efferocytic “M2c” monocytes/macrophages may
have a role in immunopathogenesis of SLE.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by defective phagocytosis of apop-
totic cells (ACs) [1]. Accumulation and presentation of
AC-derived nuclear and membrane autoantigens in
lymphoid organs are believed to drive the activation of
autoreactive B and T cells, leading to production of anti-
nuclear and antiphospholipoprotein autoantibodies.
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reproduction in any medium, provided the orantibody-opsonized ACs bind to Toll-like receptors
(TLRs) and immunoglobulin G Fc receptors (FcγRs) on
innate immune cells, provoking aberrant production of
type I interferons α and β (IFN-α/β) and proinflammatory
cytokines [2,3]. Additionally, noningested ACs undergo
secondary necrosis, which fuels ongoing innate inflamma-
tion by amplifying TLR activation and oxidative burst
[4,5].
Clearance of ACs is crucial for resolution of inflamma-
tion and maintenance of immune tolerance [6]. In healthy
individuals, discrete populations of phagocytes, called
M2c (CD163+) macrophages, are designated to promptly
remove ACs, including activated immune cells undergoing
apoptosis [7-9]. Moreover, the physiologic engulfment oftd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inflammatory cytokines [6].
The Mer receptor tyrosine kinase (MerTK), which
belongs to the family of Tyro3, Axl and MerTK (TAM)
receptors (TAMRs), is required for the efficient clear-
ance of ACs exerted by M2c monocytes/macrophages
[9], participates in immune regulation by stimulating
interleukin 10 (IL-10) secretion [9-11] and is involved in
restoration of tissue homeostasis after inflammatory
processes as well as in the maintenance of central and
peripheral tolerance [11-14]. Another member of the
TAMR family, Axl, is importantly involved in the deactiva-
tion of innate immune cells stimulated by TLR agonists
and type I IFNs through recruitment of suppressors of
cytokine signaling 1 and 3 and the transcriptional re-
pressor Twist [15-17]. Both MerTK and Axl inhibit
TLR-induced activation of nuclear factor κB (NF-κB)
transcription factors and production of proinflamma-
tory cytokines such as tumor necrosis factor α (TNF-α)
and IL-6 [9-11,15-17].
Both the Mer and Axl receptors are susceptible to
posttranslational regulation through ectodomain shed-
ding mediated by a disintegrin and metalloprotease do-
main (ADAM) metallopeptidases [18-20]. In the present
study, we measured the soluble (s) ectodomains sMer
and sAxl in the circulation of SLE patients and matched
healthy individuals with the aim of investigating how
these molecules relate to clinical, laboratory and im-
munological profiles of SLE; how they are related to
each other and to the TAMR ligands growth arrest–
specific 6 (Gas6) and reduced free Protein S (ProS); and
under what immunological conditions they are pro-
duced. We found that plasma levels of both sMer and
sAxl were related to general aspects of systemic auto-
immunity and were associated with hematological and
renal involvement. However, sMer and sAxl did not sig-
nificantly correlate with each other. Compared to sAxl,
sMer showed closer relations with specific aspects of
SLE immunopathogenesis, such as production of lupus-
specific autoantibodies and reduction of free ProS in cir-
culation. Strong correlations with disease activity indices
were found for sMer, but not for sAxl. Patients with
signs of active SLE showed higher levels of sMer com-
pared to matched controls. Remarkably, sMer levels in
SLE patients directly correlated with circulating levels of
sCD163, a well-known marker of M2 activation, and
sCD163 levels correlated with Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) score. In fact,
sMer and sCD163 were found to be released under the
same M2c polarizing conditions. Production of sAxl was
instead enhanced in the presence of IFN-α or IFN-β,
and plasma concentrations of sAxl in SLE patients
correlated with increased Gas6 levels. Our data high-
light, through the study of sMer and sCD163, a strictrelationship between SLE pathogenesis and homeostasis
of anti-inflammatory and efferocytic M2c monocytes/
macrophages. We also provide indirect proof, through the
study of sAxl, that type I IFN stimulation plays a role in
the development of systemic autoimmunity but does not
seem to be closely related to SLE disease activity. Whether
augmented ectodomain shedding of membrane receptors
reflects increased turnover and/or activation of the re-
spective pathways or rather contributes to their dysfunc-
tion and/or inhibition remains to be clarified.
Methods
Participants
Plasma samples from 107 SLE patients participating in
the Oklahoma Cohort for Rheumatic Disease were stud-
ied. All patients satisfied at least four of the 1982 revised
American Rheumatism Association criteria for SLE [21].
Forty-five of these patients were matched to healthy
controls by age, gender and ethnicity. Clinical and labora-
tory data were registered into a database which included
no personal identifiers. The characteristics of the pa-
tients and the controls enrolled are reported in Table 1.
Heparinized plasma samples were collected and stored
at −70°C immediately after collection. Disease activity
was scored using the SLEDAI and the British Isles Lupus
Assessment Group (BILAG) index [22,23]. Levels of com-
plement fractions C3 and C4 were determined by immu-
noturbidity. Total 50% hemolytic complement (CH50)
activity was calculated by using a liposome immunoassay.
Antinuclear antibodies were detected by indirect im-
munofluorescence. The Crithidia luciliae test was used
for detection of anti-double-stranded DNA (anti-dsDNA).
Antiextractable nuclear antigen (anti-ENA) autoantibodies
were measured by Ouchterlony double-immunodiffusion.
Prior to participation, all participants gave their informed
consent to donate their blood samples. The study was
approved by the institutional review boards of the Okla-
homa Medical Research Foundation and Temple University.
Cell cultures
Monocytes from buffy coats of healthy blood donors were
isolated with Ficoll-Paque PLUS gradient (GE Healthcare
Life Sciences, Pittsburgh, PA, USA) and by magnetic
separation using a kit for human monocyte enrichment
by negative selection (EasySep cell isolation platform;
STEMCELL Technologies, Vancouver, BC, Canada) ac-
cording to the manufacturer’s instructions. The purity of
CD14+ cells was >90% as assessed by flow cytometry.
CD14+ cells were cultured for 3 days at 0.8 × 106 cells/ml
in 24-well plates containing serum-free X-VIVO 15
medium (Lonza, Walkersville, MD, USA) in the pres-
ence or absence of macrophage colony-stimulating
factor (M-CSF) (50 ng/ml; PeproTech, Rocky Hill, NJ,
USA), granulocyte macrophage colony-stimulating
Table 1 Demographic, clinical and immunological characteristics of the patientsa
Characteristics Total patients Matched patients Matched controls
(N = 107) (N = 45) (N = 45)
Age (years) 39.6 ± 14.1 46.7 ± 15.4 45.4 ± 15.9
Sex (F:M ratio) 3.9:1 3.1:1 3.1:1
Ethnicity
Caucasian (%) 88.9 86.9 86.9
African (%) 6.7 6.5 6.5
Asian (%) 2.2 3.7 3.7
American Indian (%) 2.2 2.8 2.8
ACR total (number of criteria met) 5.51 ± 1.69 5.52 ± 1.69
Antichromatin Ab 32.7 28.9
Anti-dsDNA Ab (Crithidia luciliae test) (%) 27.1 33.3
Anticardiolipin IgG Ab (%) 38.3 28.9
LAC (%) 13.1 11.1
Anti-Smith Ab (%) 18.7 11.1
Anti-RNP Ab (%) 20.6 17.8
Anti-Ro/SSA (Ro52/60 kDa) Ab (%) 38.3 (21.5/34.6) 31.1 (17.8/28.9)
Anti-La/SSB (anti-Ro60 + anti-La) Ab (%) 16.8 (15.0) 15.6 (13.3)
CH50 <40 (U/ml) 51.4 55.6
C4 <16 (mg/dl) 35.5 44.4
SLEDAI score 5.29 ± 4.20 5.02 ± 3.26
Renal involvement (%) 13.1 24.4
(BILAG grades A to C)
Mucocutaneous involvement (%) 68.2 57.8
Musculoskeletal involvement (%) 77.6 66.7
Cardiovascular/respiratory involvement (%) 14 15.6
Hematological involvement (%) 37.4 31.1
Vasculitis (%) 53.3 53.3
Neurological involvement (%) 3.7 4.4
BILAG total score 6.17 ± 4.53 5.70 ± 3.93
Gas6 plasma levels (ng/ml) 18.81 ± 8.67 17.64 ± 7.10 15.89 ± 6.88
Free protein S plasma levels (μg/ml) 6.78 ± 2.36 6.37 ± 1.79 6.91 ± 1.74
aAb, antibody; ACR total, number of American Rheumatism Association 1982 revised criteria for classification of systemic lupus erythematosus; BILAG, British Isles
Lupus Assessment Group index; C4, complement fraction 4; CH50, 50% hemolytic complement activity of serum; dsDNA, double-stranded DNA; Gas6, growth
arrest–specific 6; IgG, immunoglobulin G; LAC, lupus anticoagulant; RNP, ribonucleoprotein; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SSA,
Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B.
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(50 ng/ml; PeproTech), IFN-α (3,000 U/ml; Novus Bi-
ologicals, Littleton, CO, USA), IFN-β (3,000 U/ml;
PeproTech), IFN-γ (2.5 ng/ml; R&D Systems, Minneap-
olis, MN, USA), IL-4 (20 ng/ml; Novus Biologicals), IL-17
(100 ng/ml; R&D Systems) or dexamethasone (100 nM;
Sigma-Aldrich). When specified, on day 2, cells were coin-
cubated with lipopolysaccharide (LPS) (100 ng/ml; Sigma-
Aldrich) for the remaining 24 hours. Cells were then
harvested by centrifugation. Supernatants were collected
and immediately stored at −20°C for a few days before
being tested by enzyme-linked immunosorbent assay(ELISA). Pellets were resuspended in phosphate-buffered
saline (PBS) and immediately analyzed by flow cytometry.
Enzyme-linked immunosorbent assay
Plasma concentrations of sAxl, sMer and sCD163 were
measured by sandwich ELISA according to standard
procedures [24]. Briefly, 96-well plates were precoated
overnight with a capture antibody. Heparinized plasma
samples were diluted 1:10 in PBS containing 1% bovine
serum albumin (BSA) and applied to precoated plates in
duplicate. Serial dilutions of purified recombinant Axl,
MerTK or CD163 proteins were used to construct a
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For in vitro studies, cell culture supernatants were not di-
luted, and blank wells received serum-free X-VIVO 15
medium. Antigens were detected by a secondary biotin-
conjugated antibody and horseradish peroxidase–conjugated
streptavidin (BioLegend, San Diego, CA, USA). The plate
was developed with 3,3′, 5,5′-tetramethylbenzidine sub-
strate. The reaction was stopped with 2 N sulfuric acid.
Absorbance was detected at 450 nm and read with a refer-
ence wavelength set at 570 nm using a VersaMAX ELISA
microplate reader (Molecular Devices, Sunnyvale, CA,
USA). The optical density for each point was the average
of duplicate samples. Concentrations were determined
using SoftMax software (Molecular Devices) by applying
four-parameter logistic regression to the standard curve.
For sAxl quantitation, we used a mouse monoclonal anti-
Axl Ab (clone 108724; R&D Systems) for capture, recom-
binant human Axl (R&D Systems) for the standard curve
and a biotinylated goat polyclonal anti-Axl Ab (R&D Sys-
tems) for detection. For sMer quantitation, we used the
Human Total Mer DuoSet IC (DYC891; R&D Systems)
according to the manufacturer’s instructions. For sCD163
quantitation in plasma samples, we used the Human
CD163 Quantikine ELISA Kit (DC1630; R&D Systems)
according to the manufacturer’s instructions. For sCD163
quantitation in supernatants, we used a mouse monoclo-
nal anti-CD163 Ab (clone EDHu-1; Novus Biologicals) for
capture, recombinant human CD163 (R&D Systems) for
the standard curve and a biotinylated goat polyclonal anti-
CD163 Ab (R&D Systems) for detection.
Flow cytometry
Membrane expression levels of Axl, MerTK and CD163
were measured in cultured monocytes after being washed
in buffer containing 2% BSA. Monocytes were gated on
the basis of forward and side light scatter and by using a
phycoerythrin/cyanin 7 (PE/Cy7)-conjugated anti-CD14
antibody (BioLegend). The following mouse monoclonal
antibodies were used for detection: PE-conjugated anti-
MerTK (clone 125518; R&D Systems), PE-conjugated
anti-Axl (clone 108724; R&D Systems) and allophycocya-
nin (APC)-conjugated anti-CD163 (clone GHI/61; BioLe-
gend). Expression levels were evaluated using appropriate
PE-labeled and APC-labeled isotype controls (BioLegend).
Cells were analyzed using a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA) and FlowJo software
(Tree Star, Ashland, OR, USA).
Statistical analysis
Data are expressed as means ± SD. Comparisons of soluble
receptor levels between patients and matched controls
or between groups of patients with different labora-
tory or clinical characteristics were made using the Mann-
Whitney U test. Correlations between soluble receptorlevels and other continuous laboratory data were ana-
lyzed using Spearman’s rank correlation coefficient.
Correlations of soluble receptor levels with the weighted
scales of SLEDAI and the total BILAG index were
made using Pearson’s correlation coefficient. Compari-
sons in soluble receptor levels among patients with
inactive, moderately active or very active SLEDAI
scores were made using one-way analysis of variance
(ANOVA) with the Newman-Keuls multiple compari-
son test. For in vitro studies, differences between cell
treatment groups were calculated using a paired Stu-
dent’s t-test or one-way repeated-measures ANOVA
(Newman-Keuls post hoc analysis) when more than
two treatment groups were compared. Prism software
(GraphPad Software, La Jolla, CA, USA) was employed
for all analyses and graphing. A P value <0.05 was consid-
ered statistically significant.
Results
Plasma concentrations of sMer are increased in discrete
SLE patient subsets compared to matched healthy
controls
We compared plasma levels of sAxl and sMer in 45 SLE
patients and 45 age-, gender- and ethnicity-matched
normal controls. No significant differences were ob-
served between the two whole groups for either sAxl
(27.21 ± 13.51 ng/ml vs. 28.56 ± 13.52 ng/ml) or sMer
(15.68 ± 8.15 ng/ml vs. 13.30 ± 4.36 ng/ml) (Figure 1A).
However, by subdividing patients with active disease
(SLEDAI score ≥6) from those in remission (SLEDAI <6),
we were able to note higher levels of sMer in the circula-
tion of active patients compared to matched healthy indi-
viduals (16.67 ± 10.35 ng/ml vs 11.80 ± 4.04 ng/ml,
respectively), although full statistical significance was not
reached (P = 0.0532) (Figure 1A). Similarly, sMer concen-
trations were higher in patients with active renal dis-
ease (according to BILAG renal score) than in matched
controls (21.53 ± 12.31 ng/ml vs. 13.51 ± 3.21 ng/ml;
P = 0.0537) (Figure 1B). Significant increases in sMer
levels compared to healthy controls were observed in
patients with antibody positivity for anti-dsDNA (21.70 ±
8.36 ng/ml vs. 13.68 ± 4.08 ng/ml; P = 0.0391) (Figure 1C)
and anti-Sjögren’s syndrome antigen A/Ro 60 kDa (SSA/
Ro60) (17.64 ± 6.05 ng/ml vs. 11.86 ± 3.84 ng/ml;
P = 0.0137) (Figure 1D). For sAxl, no differences were noted
between the subsets of patients and matched controls, ex-
cept for a trend toward higher levels in the circulation of
anti-dsDNA-positive patients (31.64 ± 10.22 ng/ml vs.
25.05 ± 11.85 ng/ml; P = 0.0547) (Figure 1C). No differences
were noted in plasma levels of sMer and sAxl compared
to matched controls when considering patients with anti-
phospholipid antibodies (Figure 1E) or other anti-ENA
autoantibodies or in patients with active hematological or
vascular active disease (not shown).
Figure 1 Plasma levels of soluble Mer are increased in discrete subsets of systemic lupus erythematosus patients. Levels of soluble Mer
(sMer) or soluble Axl (sAxl) of 45 patients (pts) and 45 healthy controls (ctrls) were measured and compared by considering the whole groups
(A) or by dividing patients and matched controls into subgroups according to disease activity (A), organ involvement (B) and autoantibody
specificities (C, D and E). αCL, anticardiolipin immunoglobulin G; αDNA, anti-double-stranded DNA; αRo60, anti-Sjögren’s syndrome antigen
A/Ro 60 KDa; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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involvement, but only sMer correlates with SLE activity
We examined the entire cohort of 107 matched and
unmatched SLE samples to look for potential differences
in sAxl and sMer levels among patients according to
organ involvement, laboratory parameters and clinical
indices of lupus disease activity. We found that plasma
concentrations of both sAxl and sMer were higher in pa-
tients with stable or active BILAG hematological in-
volvement (that is, whose BILAG score was not zero)
compared to patients with inactive or no hematological
involvement (sAxl: 34.20 ± 12.72 vs 27.61 ± 10.62 ng/ml,
P = 0.0057. sMer: 19.18 ± 7.85 vs. 13.92 ± 5.97 ng/ml,
P = 0.0002) (Figure 2A), as well as in patients with stable
or active BILAG renal involvement compared to pa-
tients with inactive or no renal involvement (sAxl: 35.75 ±
13.58 vs. 28.79 ± 10.99, P = 0.0115. sMer: 21.80 ± 11.33 vs.
15.42 ± 6.96 ng/ml, P = 0.0240) (Figure 2B). Concentrationsof sMer levels, but not sAxl, directly correlated with BILAG
total score (r = 0.20; P = 0.0387) (Figure 2C).
In fact, only for sMer did we find strong associations
with lupus disease activity markers. Circulating levels
of sMer were inversely correlated with C3 (r = −0.27;
P = 0.0049) (Figure 3A) and C4 values (r = −0.25; P =
0.0053) (Figure 3B), whereas sAxl levels had only bor-
derline relations with lower C3 levels (r = −0.17; P =
0.0840) (Figure 3A). In accord with these data, signifi-
cantly higher levels of sMer were found in patients with a
clear-cut reduction in C3 (22.24 ± 9.30 ng/ml vs. 14.79 ±
6.10 ng/ml; P = 0.0010 (not shown)) or in C4 (18.70 ±
7.91 ng/ml vs. 14.48 ± 6.32 ng/ml; P = 0.0029) (Figure 3C)
according to our laboratory cutoff values (C3 <86 mg/dl
and C4 <16 mg/dl). A less marked difference in sAxl
values was noted between patients with low or normal
C3 levels (36.76 ± 15.10 ng/ml vs. 28.99 ± 10.78 ng/ml;
P = 0.0397 (not shown)), whereas no difference was
Figure 2 Soluble Axl and soluble Mer levels are associated with British Isles Lupus Assessment Group index hematological and renal
involvement, and soluble Mer is also associated with total BILAG score. Levels of soluble Axl (sAxl) or soluble Mer (sMer) were measured in
107 matched and unmatched patients and compared according to active and/or stable (BILAG score ≥1) or inactive and/or absent (BILAG = 0)
organ involvement (A) and (B). Associations with total BILAG score were then calculated (C). BILAG, British Isles Lupus Assessment Group index;
hematol, hematological.*P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant.
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(32.19 ± 12.83 ng/ml vs. 29.14 ± 11.21 ng/ml) (Figure 3C).
Moreover, levels of sMer, but not of sAxl, were directly
correlated with titers of circulating anti-dsDNA autoanti-
bodies (r = 0.29; P = 0.0032) (Figure 3D). Circulating levels
of sMer showed a strong direct correlation with SLEDAI
scores (r = 0.34; P = 0.0004) (Figure 3E), whereas only a
trend could be detected for sAxl (r = 0.17; P = 0.0745).
Accordingly, patients with very active disease (SLEDAI
score ≥9) showed the highest levels of sMer in the circula-
tion (20.88 ± 10.47 ng/ml), which was significantly differ-
ent compared to patients with low or moderate disease
activity (15.32 ± 7.08 ng/ml; P < 0.05) and even more sig-
nificantly different from patients in complete remission
(SLEDAI score <3, 14.74 ± 4.20 ng/ml; P < 0.01). No sig-
nificant differences in sAxl levels were observed among
these subsets of patients (Figure 3F).
sAxl and sMer levels are associated with production of
autoantibodies, but only sMer relates to lupus-specific
autoimmunity
Both sAxl and sMer were associated with the presence
of circulating autoantibodies against nuclear material
and phospholipids. Plasma concentrations of sAxl and
sMer were higher in patients positive for antichromatin
(sAxl: 35.28 ± 13.33 ng/ml vs. 27.74 ± 10.26 ng/ml; P=
0.0018. sMer: 19.41 ± 8.87 ng/ml vs. 14.26 ± 5.51 ng/ml;
P= 0.0015) (Figure 4A) and anticardiolipin antibodies(sAxl: 33.92 ± 13.18 ng/ml vs. 28.42 ± 10.88 ng/ml; P =
0.0462. sMer: 18.27 ± 8.01 ng/ml vs. 14.83 ± 6.78 ng/ml; P
= 0.0234) (Figure 4B). sAxl levels also correlated with
lupus anticoagulant (LAC) positivity (36.36 ± 9.51 ng/ml
vs. 29.19 ± 11.60 ng/ml; P = 0.0109) (Figure 4C). Neverthe-
less, only sMer levels were significantly higher in the pres-
ence of lupus-specific autoantibodies, such as anti-dsDNA
(18.86 ± 7.78 ng/ml vs. 14.86 ± 6.65 ng/ml; P = 0.0092)
(Figure 4D), anti-Smith (anti-Sm) (20.98 ± 9.40 ng/ml vs.
14.81 ± 6.08 ng/ml; P = 0.0064) (Figure 4E), antiribonu-
cleoprotein (anti-RNP) (20.39 ± 9.52 ng/ml vs. 14.81 ±
6.01 ng/ml; P = 0.0070) (Figure 4F) and anti-Ro/SSA
(18.42 ± 7.78 ng/ml vs. 14.40 ± 6.33 ng/ml; P = 0.0041)
(Figure 4G). In particular, sMer levels were increased in
patients positive for anti-Ro60 (19.19 ± 7.77 ng/ml vs.
14.23 ± 6.23 ng/ml; P = 0.0004), but not for anti-Ro
52 kDa autoantibodies (Figure 4G) and more specifically
in those without concomitant positivity of anti-La/
Sjögren’s syndrome antigen B (anti-La/SSB; 21.27 ±
9.08 ng/ml in patients with anti-Ro60 alone (P = 0.0006) vs.
16.58 ng/ml ± 4.85 ng/ml in patients positive for
both anti-Ro60 and anti-La (P = 0.0575); not shown).
A trend toward higher plasma levels of sAxl was
observed in anti-dsDNA-positive patients (33.50 ±
12.47 ng/ml vs. 29.00 ± 11.44 ng/ml; P = 0.0535) (Figure 4D),
whereas no difference could be detected in sAxl
levels on the basis of anti-ENA autoantibody positivity
(not shown).
Figure 3 Plasma levels of soluble Mer, but not soluble Axl, are closely associated with disease activity. Levels of soluble Axl (sAxl) and
soluble Mer (sMer) were analyzed according to levels of complement fraction 3 (C3) (A) and C4 (B) and (C), circulating titers of anti-double-
stranded DNA (anti-dsDNA) antibodies (D) and SLEDAI scores (E) and (F). SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. *P < 0.05;
**P < 0.01; ***P < 0.001; n.s., not significant.
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correlated with levels of Gas6 and ProS
Correlation between sAxl and sMer plasma levels did
not reach full statistical significance in SLE patients
(r = 0.18; P = 0.0675) (Figure 5A). We found significant
correlations between concentrations of sAxl and sMer,
as well as plasma levels of their ligands Gas6 and free
ProS, previously measured in the same cohort [24].However, sAxl and sMer correlated differently with Gas6
and ProS. sAxl was directly correlated with Gas6 levels (r
= +0.31; P = 0.0011) (Figure 5B), but sMer was inversely
correlated with free ProS levels (r = −0.26; P = 0.0088). Ac-
cordingly, a significant difference in concentrations of Axl,
but not of sMer, was found between patients with high vs.
low Gas6 levels (32.86 ± 11.33 ng/ml vs. 27.33 ± 11.95 ng/
ml; P = 0.0050) (Figure 5D), whereas a significant difference
Figure 4 Plasma levels of soluble Mer, but not soluble Axl, correlated with lupus autoantibody specificities. Levels of soluble Axl (sAxl)
and soluble Mer (sMer) were analyzed according to the presence or absence of the following antibodies: antichromatin (αchrom) (A),
anticardiolipin immunoglobulin G (IgG) (αCL) (B), lupus anticoagulant (LAC) (C), anti-double-stranded DNA (αdsDNA) (D), anti-Smith (αSm) (E),
antiribonucleoprotein (αRNP) (F), anti-Sjögren’s syndrome antigen A (SSA)/Ro 52 and 60 KDa (αRo52 and αRo60) and anti-Sjögren’s syndrome
antigen B (SSB)/La (G). *P < 0.05; **P < 0.01; ***P < 0.001.
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between patients with high or low free ProS (13.64 ±
5.43 ng/ml vs. 17.21 ± 6.68 ng/ml; P = 0.0021) (Figure 5E).
Cutoff values of Gas6 and free ProS (16.5 ng/ml and
6.5 μg/ml, respectively) were established according to their
mean values among patients and matched healthy controls
(Table 1). In healthy controls, we failed to find significant
correlations (not shown).
sMer is an M2c activation marker, whereas sAxl is a type-I
IFN stimulation marker
We investigated whether the release of sMer and sAxl
was related to discrete immunological phenotypes of
monocytes/macrophages. For this purpose, we measuredconcentrations of sMer and sAxl in supernatants of
monocytes/macrophages cultured in the presence of
medium alone (M0), IFN-γ or GM-CSF (M1), IL-17 (M17),
IL-4 (M2a), IL-10, M-CSF, M-CSF plus IL-10, or glucocorti-
coids (M2c), transforming growth factor β (TGF-β) and
combinations of M2 cytokines such as TGF-β plus IL-4 or
IL-4 plus IL-10 (other M2 activation states).
We found that sMer was abundantly released by M2c
cells, driven by M-CSF plus IL-10 or by glucocorticoids
(dexamethasone). A slight decrease in sMer levels was
noted in the supernatants of M1 cells, driven by IFN-γ
(Figure 6A). By contrast, concentrations of sAxl were not
significantly influenced by either M1 or M2 polarization
(Figure 6B).
Figure 5 Plasma levels of soluble Axl correlated with growth arrest–specific 6, but soluble Mer correlated with reduced free Protein S.
Levels of soluble Axl (sAxl) and soluble Mer (sMer) were related to each other (A) and to Tyro3, Axl and MerTK (TAM) receptor ligands growth
arrest–specific 6 (Gas6) and free Protein S (ProS) (B, C, D, and E). Cutoff values of Gas6 (ng/ml) and ProS (μg/ml) were established by considering
mean values in patients and controls (Table 1). **P < 0.01; n.s., not significant.
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relations between either sMer or sAxl levels and plasma
concentrations of sCD163, a well-known marker of
M2c cell activation. In accord with the in vitro data,
we found that circulating levels of sMer were strongly
associated with plasma concentrations of sCD163 (r = 0.50;
P = 0.0011) (Figure 6C), whereas no significant correlation
was observed between sAxl and sCD163 levels (r = +0.17;
P = 0.2978) (Figure 6D). Levels of sCD163 were associated
with positivity of antichromatin autoantibodies (988.22 ng/
ml ± 299.05 ng/ml vs. 747.34 ng/ml ± 300.38 ng/ml; P =
0.0255) (Figure 6E), and, as observed for sMer, correlated
with lupus disease activity as assessed by SLEDAI score
(r = 0.35; P = 0.0257) (Figure 6F).
Because SLE is characterized by the so-called “inter-
feron signature” [25,26], we subsequently examined the
role of type I IFNs in regulating the release of sAxl, sMer
and sCD163 and looked at the effects of combining type
I IFNs (IFN-α and IFN-β) with macrophage growth fac-
tors (M-CSF and GM-CSF) and/or with M2c polariz-
ing agents (IL-10 or dexamethasone). Ectodomainshedding of membrane receptors and consequent re-
lease of soluble receptors was triggered by using low
doses of LPS.
Release appeared to be moderately enhanced in the
presence of LPS alone, although no statistically signifi-
cant difference was reached (Figure 7A to C). Levels of
sMer and sCD163 were confirmed to be highest upon
exposure to M2c polarizing stimuli. M-CSF was required
in combination with IL-10 to enhance sMer production,
but it was not required for sCD163. Stimulation with ei-
ther IFN-α or IFN-β alone failed to exert significant effects
on either sMer or sCD163 levels (Figures 7A and B).
By contrast, both IFN-α and IFN-β were found to
stimulate significant production of sAxl, with IFN-β
stimulating the highest levels. The addition of M-CSF or
GM-CSF enhanced IFN-α effects, although the differ-
ences did not reach full statistical significance. Stimula-
tion with M2c agents alone did not influence sAxl
production (Figure 7C).
Combining M2c polarizing conditions (M-CSF plus
IL-10) with IFN-α exposure had variable effects. IFN-α
Figure 6 Soluble Mer is released by M2c monocytes/macrophages and correlates with circulating levels of soluble CD163 in systemic
lupus erythematosus, and soluble CD163, like soluble Mer, correlates with Systemic Lupus Erythematosus Disease Activity Index score.
Levels of soluble Mer (sMer) (A) and soluble Axl (sAxl) (B) were measured in supernatants of monocytes/macrophages cultured for 3 days in the
presence of medium alone (resting M0), interferon γ (IFN-γ), granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 17 (IL-17)
(classically activated and/or proinflammatory M1 and M17), IL-4, transforming growth factor β (TGF-β), IL-10, macrophage colony-stimulating factor
(M-CSF), dexamethasone (Dex), alone or in combination (alternatively activated and/or regulatory M2a and M2c cells). In 40 consecutive patients in our
cohort, potential correlations between plasma levels of sMer (C) or sAxl (D) and soluble CD163 (sCD163) were examined. Levels of sCD163 were also
analyzed according to circulating autoantibodies (E) and disease activity (F). αchrom., antichromatin; SLEDAI, Systemic Lupus Erythematosus Disease
Activity Index. *P < 0.05; **P < 0.01; n.s., not significant.
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(Figure 7A). Conversely, M-CSF plus IL-10 enhanced
sAxl production induced by IFN-α (Figure 7B). IFN-α
neutralized the modulatory effect of M-CSF on sCD163
production induced by IL-10 (Figure 7C).
Release of soluble ectodomains mirrored membrane ex-
pression patterns of the respective receptors MerTK, Axl
and CD163 in the absence of LPS. M-CSF, IL-10 and
dexamethasone induced MerTK and CD163 expression,
and IFN-α stimulated Axl expression. Furthermore, IFN-α
reduced MerTK upregulation driven by M-CSF plus IL-
10, whereas M-CSF plus IL-10 enhanced Axl upregulation
driven by IFN-α. IFN-α neutralized the modulatory effect
of M-CSF on CD163 upregulation driven by IL-10. Con-
sistent with its role as a sheddase agonist [17,19,20,27],
LPS decreased surface expression of MerTK and CD163
induced by M-CSF, IL-10 and dexamethasone, as well as
surface expression of Axl induced by IFN-α (Figure 7D).Discussion
SLE is characterized by impaired macrophage phagocyt-
osis of ACs [1], delayed and proinflammatory AC clear-
ance [2,3] and increased cellular expression of the type I
IFN-inducible gene spectrum: the so-called IFN “signature”
[25,26]. All these events reflect and contribute to aber-
rant stimulation of innate immunity. The family of
the TAMRs acts to impede such events, thereby pre-
venting systemic autoimmunity. In particular, MerTK
is key to efficient clearance of early ACs and to
macrophage production of anti-inflammatory cyto-
kines [9-14], and Axl is primarily involved in feed-
back pathways controlling type I IFN-mediated innate
immune activation [15-17]. In the present study, we
analyzed the levels of sAxl and sMer receptors in the
circulation of SLE patients and investigated potential
relations with the clinical, laboratory and immuno-
logical aspects of the disease.
Figure 7 (See legend on next page.)
Zizzo et al. Arthritis Research & Therapy 2013, 15:R212 Page 11 of 15
http://arthritis-research.com/content/15/6/R212
(See figure on previous page.)
Figure 7 Interferon α/β is required for production of soluble Axl, and combining M2c polarizing conditions with type I interferon
exposure inhibits soluble Mer production and enhances soluble Axl release. Levels of soluble Mer (sMer) (A), soluble CD163 (sCD163)
(B) and soluble Axl (sAxl) (C) were measured in supernatants of monocytes/macrophages cultured for 3 days in the presence or absence of type I
interferons (IFN-α or IFN-β), macrophage growth factors (macrophage colony-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating
factor (GM-CSF)), M2c polarizing agents (interleukin 10 (IL-10) or dexamethasone) or combinations of these. On day 2, low doses of lipopolysaccharide
(LPS) were added for an additional 24 hours to stimulate ectodomain shedding of membrane receptors. Surface expression levels of Mer receptor
tyrosine kinase (MerTK), Axl and CD163 were measured by flow cytometry (D). Numbers shown in (D) refer to mean fluorescence intensity values.
Data are representative of three independent experiments. Dex, dexamethasone. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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are associated with general traits of systemic immunity,
such as antinuclear and antiphospholipid autoantibody
positivity. Additionally, both correlated with hematologic
and renal involvement. Nevertheless, we found that
sMer, but not sAxl, was significantly associated with
lupus-specific humoral autoimmune responses, which
were characterized by production of anti-dsDNA, anti-
Sm, anti-RNP and anti-Ro60 autoantibodies. Remark-
ably, only sMer showed strong correlations with disease
activity indices, such as C3 and C4 reduction, circulating
titers of anti-dsDNA and SLEDAI and total BILAG
scores. Compared to matched healthy controls, plasma
levels of sMer, but not sAxl, were found to be higher
in patients with active lupus (SLEDAI score ≥6), active
BILAG renal score and anti-dsDNA and anti-Ro60 positiv-
ity. The highest values of sMer were observed in patients
with very active lupus (SLEDAI score ≥9). Differences
between sAxl and sMer also included relations with their
ligands, Gas6 and ProS. In particular, sAxl directly
correlated with Gas6 levels, whereas sMer correlated with
reduced levels of free ProS. Notably, we found that sAxl
and sMer were produced by different immune phenotypes
of monocytes/macrophages. sAxl release was induced in
the presence of either IFN-α or IFN-β, and sMer was re-
leased by M2c differentiated cells, similarly to what we ob-
served for sCD163, a well-known marker of M2 activation.
In fact, concentrations of sMer in the circulation of lupus
patients directly correlated with plasma levels of sCD163,
and sCD163, similarly to sMer, significantly correlated with
disease activity. Combining type I IFN exposure with M2c
polarizing conditions reduced M2c-driven sMer produc-
tion while increasing IFN-α-induced sAxl release. The
prototypical T-helper cytokines IFN-γ, IL-4 and IL-17 did
not exert significant influences on either sAxl or sMer
production.
To the best of our knowledge, herein we describe for
the first time sMer as a biomarker of M2c activation, in
parallel with sCD163. We confirmed the correlation be-
tween SLEDAI scores and plasma levels of sMer re-
ported by Wu et al. [28] and Recarte-Pelz et al. [29]. We
also have shown a direct correlation of sMer with
sCD163 levels and a significant correlation betweenSLEDAI and sCD163 levels. Our data strongly suggest a
strict relation between SLE activity and M2c homeosta-
sis, in agreement with recent data from Nakayama et al.
showing sCD163 associations with anti-dsDNA positivity
and leukopenia [30]. Similarities between sMer and
sCD163, with regard to their expression patterns and
their associations in SLE, are consistent with the fact
that their respective membrane receptors MerTK and
CD163 are both upregulated on the surface of regulatory
M2c monocytes/macrophages [9]. Both are cleaved by
the same metalloproteinase, ADAM-17 [20,27], in con-
trast to sAxl, which is cleaved by ADAM-10 [18]. Both
MerTK and CD163 serve to trigger IL-10 release from
M2c cells [9,31], and both protect macrophages from oxi-
dative stress and subsequent apoptosis induced by hydro-
gen peroxide, oxidized lipoproteins or iron-containing
heme [32-34].
The biological significance of sMer and sCD163 in SLE
can be construed as due to at least two mechanisms. Cor-
relations of sMer and sCD163 with SLE activity may indi-
cate a compensatory increase in M2c activation and
turnover of monocytes and/or macrophages, with the aim
of promoting efferocytosis and immune regulation in re-
sponse to the still poorly defined inflammatory triggers
and to the increased rates of apoptosis. Alternatively, ex-
cess ectodomain shedding of MerTK and CD163 by
ADAM-17 may account for a functional impairment of
M2c monocytes/macrophages and could itself contribute
to chronic inflammation, defective clearance of early ACs
and autoimmunity. It is known, in fact, that TAMR-
knockout mice develop hyperreactive immune responses
and severe lymphoproliferation [11,35]. In particular, dis-
rupted MerTK expression is associated with a SLE-like
syndrome in mice [36], and gene polymorphisms of
MerTK and Gas6 are associated with clinical manifesta-
tions in SLE patients [37,38]. Besides gene defects and
polymorphisms, posttranslation inhibition of these mo-
lecular pathways through ectodomain shedding may affect
efferocytosis and regulatory responses [19], thus favoring
accumulation of AC-derived autoantigens. ADAM metal-
loproteinases are, in fact, activated upon multiple condi-
tions, including infections, oxidative stress and paracrine
signals [18-20,27,39-42]. Of note, ADAM-17 is also
Zizzo et al. Arthritis Research & Therapy 2013, 15:R212 Page 13 of 15
http://arthritis-research.com/content/15/6/R212known to cleave and inhibit the membrane receptor
for M-CSF [43], which is needed for complete M2c dif-
ferentiation [9]. Besides its crucial role in promoting
macrophage release of major proinflammatory mediators,
including TNF-α and IL-6 [40], ADAM-17 may thus exert
its proinflammatory effects by interfering with differenti-
ation and activity of regulatory M2c macrophages. From
this perspective, impeding ectodomain shedding by the
use of safe and selective ADAM inhibitors might help to
restore macrophage homeostasis in SLE [44].
Cleavage of Axl into sAxl may in turn alter the
homeostatic mechanisms regulating TLR-mediated acti-
vation [15,16], thus resulting in exaggerated production
of IFN-α in response to AC-derived autoantigens. Excess
activation of TLR/IFN pathways may ultimately lead to
dendritic cell maturation, presentation of autoantigens
to autoreactive T cells, chronic B-cell activation, oligo-
clonal expansion of plasmablasts and production of
autoantibodies [26]. In addition, both sMer and sAxl are
able to sequester the ligand Gas6 [18,19,45], thus inter-
fering with membrane TAMR-induced regulatory signal-
ing. Contrary to Ekman et al. [46], however, we could
not confirm a significant association between SLEDAI
scores and plasma levels of sAxl. Similarly, Recarte-Pelz
et al. [29] failed to find such an association. The discrep-
ancy might be due to differences between patient popu-
lations or to the use of different detection reagents. The
same ELISA kit (R&D Systems) was used by Wu et al.
[28], Recarte-Pelz et al. [29] and our laboratory for de-
tection of sMer in SLE patients. For sAxl, instead,
Ekman et al. [46] used an ELISA type developed in their
laboratory, whereas we and Recarte-Pelz et al. [29] used
the same commercially available anti-Axl detection anti-
body (R&D Systems). The weaker association with SLE
activity of sAxl compared to sMer suggests a more indir-
ect role of sAxl in SLE pathogenesis. Whereas the cleav-
age of MerTK may be critical for the accumulation of
AC-derived autoantigens and production of pathogenic
lupus-specific autoantibodies, the cleavage of Axl could
be more generally related to uninhibited TLR activation
and production of IFN-α/β and other proinflammatory
cytokines. Consistent with this view, sAxl, but not sMer,
was found to be increased in nonautoimmune inflamma-
tory diseases such as critical limb ischemia [28,47].
Among lupus-specific autoantibodies, sMer levels
showed the strongest association with anti-Ro60 anti-
bodies, particularly in the absence of a concomitant
anti-La positivity. No association was found with anti-
Ro52 antibodies. In fact, serum positivity for anti-Ro60
best discriminated patients with significantly higher
levels of sMer compared to matched healthy controls. It
is noteworthy that Ro60 is translocated to the cell sur-
face of ACs during early apoptosis independently of La
and Ro52 [48]. Autoantibodies against surface-exposedRo epitopes are specific for a subset of SLE patients
showing positivity of anti-Ro60 without anti-La, whereas
double-positivity of anti-Ro60 and anti-La is consequent
to intermolecular spreading from Ro to La, in which
antigens are exposed on late ACs or released from
necrotic ACs [48]. Anti-Ro52 antibodies are instead more
prevalent in conditions other than SLE, such as primary
Sjögren’s syndrome and idiopathic inflammatory myop-
athies [49]. Because production of anti-Ro60 antibodies
represents a lupus-specific humoral autoimmune response
against early ACs [48] and MerTK is specifically required
for M2c macrophage phagocytosis of early ACs [9], the
strong association that we found between anti-Ro60
and sMer in SLE patients might reflect a compensa-
tory increase in M2c activation of monocytes and/or
macrophages to enhance the clearance of early ACs by
MerTK. Alternatively, the accumulation of early ACs fos-
tering anti-Ro60 production might be itself a consequence
of excess ectodomain shedding of MerTK, which would
interfere with the clearance efficiency of M2c cells. The
latter hypothesis suggests a putative role for the cleavage
of MerTK in SLE pathogenesis, at least in a subgroup of
anti-Ro60-positive patients.
Our data pertaining to the relation of sAxl and sMer to
Gas6 and ProS levels are consistent with previous data on
receptor-ligand binding affinity. Correlation between sAxl
and Gas6 is in fact consistent with the tenfold higher bind-
ing affinity of Gas6 to Axl than to MerTK [50], as well as
with the previous finding that Gas6 is primarily complexed
with sAxl in human blood [45]. Correlation between sMer
and reduced free ProS levels is consistent with the fact that
ProS binds to MerTK [50], whereas no connection be-
tween ProS and Axl has been demonstrated to date. ProS
serves as the main bridging molecule between phosphati-
dylserine on ACs and MerTK on the surface of human
monocytes and/or macrophages [8]; however, whether
sMer binds to ProS remains to be established. ProS needs
to oligomerize to bind to Mer by interacting with other
molecules of ProS on phosphatidylserine-containing
surfaces [51]. Intriguingly, ProS is also able to bind to
microparticles, besides ACs [52]. Plasma microparticles
and/or circulating ACs may therefore serve as a scaffold
for ProS oligomerization in circulation. In SLE, levels of
microparticles increase with disease activity [53],
whereas levels of free ProS decrease with disease activ-
ity [24]. It is tempting to speculate that, in active SLE
patients, ProS may bind to microparticles, thus provok-
ing reduction in free ProS levels, ProS oligomerization
and potential formation of ProS-sMer complexes. In
support of this view, it has been shown that HIV-
infected patients also show reduced free ProS levels,
and this reduction has been related to ProS binding to
circulating microparticles [54]. Further investigation is
needed to address this hypothesis.
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sMer and sCD163 are valuable biomarkers of M2c acti-
vation and disease activity in SLE. Increased levels of
sMer in SLE are also associated with lower levels of free
ProS and lupus-specific humoral immune response. sAxl
is associated with type I IFN stimulation, correlates with
Gas6 levels and shows minor associations with SLE activ-
ity and autoimmunity. Our data suggest a link between
homeostasis of efferocytic and anti-inflammatory M2c
(CD163+ and MerTK+) monocytes/macrophages and the
pathogenesis of human SLE.
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